These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Lipoprotein metabolism and beta receptor blockers].
    Author: Schauer UJ, Schauer I.
    Journal: Z Gesamte Inn Med; 1987 Apr 15; 42(8):201-5. PubMed ID: 2888241.
    Abstract:
    Including own results a survey is given of the side effects of beta-receptor blockers on the plasma lipoprotein metabolism. The formation of a from the coronary-preventive point of view unfavourable lipoprotein risk profile under influence of individual beta-receptor blockers, among others propranolol, seems to be connected with an inhibition of a key enzyme in the lipoprotein metabolism, the lecithin-cholesterol-acyl transferase. Talinolol does not show these side effects. It is recommended to control the triglyceride level and the HDL cholesterol before the induction and after the beginning of a therapy with beta-receptor blockers and to use talinolol instead of propranolol in pre-existing dyslipoproteinaemia or in unfavourable changes during the treatment.
    [Abstract] [Full Text] [Related] [New Search]